REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Research/Paper
Back to Research Library
PubMedRandomized Controlled Trial

Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial.

Sandsdal Rasmus M, Juhl Christian R, Jensen Simon B K, Lundgren Julie R, Janus Charlotte, Blond Martin B, Rosenkilde Mads, Bogh Adrian F, Gliemann Lasse, Jensen Jens-Erik B
Cardiovascular diabetology2023DOI: 10.1186/s12933-023-01765-z

Citations

0

Subjects

Non-Human

Study Context

Randomized controlled trials are the gold standard for evaluating treatment efficacy. The randomized design minimizes bias, making findings more reliable for clinical decision-making.

Why This Matters

This research contributes to the growing body of evidence on glp-1. Understanding the mechanisms and clinical applications of these peptides is an active area of investigation.

Citation

Sandsdal Rasmus M, Juhl Christian R, Jensen Simon B K et al.. (2023). Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial.. Cardiovascular diabetology. https://doi.org/10.1186/s12933-023-01765-z

View full text on PubMed

This content is derived from peer-reviewed research for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide-based therapy.